Alan Shih, MD, PhD

Icahn School of Medicine at Mount Sinai

Titles + affiliations

Assistant Professor, Department of Leukemia
Icahn School of Medicine at Mount Sinai


Screening and validating new targets in acute leukemias


AML therapy has been improved greatly with azacytidine and venetoclax combination, now a standard of care for many patients. Azacytidine targets DNA methylation, an epigenetic modification, that regulates cell development and expression of genes. Venetoclax targets a pathway that allows leukemia cells to survive. However, this combination still does not lead to cure. This proposal hypothesizes that additional agents which target these pathways – epigenetics and cell death – may lead to new treatments and augment response to the azacytidine and venetoclax combination. Using screening approaches, new epigenetic-dependency genes may be identified and lead to new targets and drugs. A novel approach that activates cell death pathways may also enhance responses.

A-Shih 300x300

Leukemia Research Foundation grant
$150K awarded in 2023

Disease focus
Acute myeloid leukemia (AML)

Research focus
Cell Biology